Trastuzumab Deruxtecan Slows Metastatic Breast Cancer

Progression - free survival longer with T - DXd versus T - DM1 for HER2+ metastatic breast cancer previously treated with trastuzumab and taxane
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news

Related Links:

J Oncol. 2021 Oct 8;2021:9657071. doi: 10.1155/2021/9657071. eCollection 2021.ABSTRACTBreast cancer is a heterogeneous disease in which genetic factors are involved in disease worsening and higher mortality. Epidemiological and clinical research revealed that breast cancer incidence continues to rise. 100 histopathologically confirmed untreated newly diagnosed cases of invasive ductal carcinoma (IDC) of breast and 100 healthy subjects were involved and blood samples were collected in non-EDTA plain vials. Serum was separated by centrifugation, total RNA was extracted from serum, and cDNA synthesis was done to study the miR...
Source: Journal of Oncology - Category: Cancer & Oncology Authors: Source Type: research
In conclusion, cell proliferation, immune response, and NAC breast cancer response was associated with MELK expression.PMID:34659896 | PMC:PMC8493385
Source: Cell Research - Category: Cytology Authors: Source Type: research
This article summarizes the milestones in the development of disitamab vedotin leading to this first approval for locally advanced or metastatic gastric cancer.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
na-Dzerve Normalization of gene expression using internal controls or reference genes (RGs) has been the method of choice for standardizing the technical variations in reverse transcription quantitative polymerase chain reactions (RT-qPCR). Conventionally, ACTB and GAPDH have been used as reference genes despite evidence from literature discouraging their use. Hence, in the present study we identified and investigated novel reference genes in SK-BR-3, an HER2-enriched breast cancer cell line. Transcriptomic data of 82 HER2-E breast cancer samples from TCGA database were analyzed to identify twelve novel genes with stab...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research
ConclusionA novel HER2-targeting ADC combined with immune checkpoint inhibitors can achieve remarkable effects in mice and elicit long-lasting immune protection in a hHER2+  murine breast cancer model. This study provides insights into the efficacy of RC48 therapeutic activity and a rationale for potential therapeutic combination strategies with immunotherapy.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractPurposeApproximately 20% of all breast cancers (BC) are HER2 amplified. In the APT trial, weekly paclitaxel/trastuzumab in node negative HER2+ BC with tumors  
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
a Antonella Pietragalla Breast cancer represents the first cause of cancer worldwide and the leading cause of cancer mortality for women. Therefore, new therapies are needed to improve the prognosis of women diagnosed with this disease. In this review, we summarize the new drug indications for the treatment of breast cancer approved by European Medicines Agency between January 2015 and June 2021. In particular, we analyzed the clinical trials results leading to approvals and their update (when available), according to setting (localized and locally advanced or metastatic) and clinical features (hormone receptor posit...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Condition:   Metastatic Breast Cancer Interventions:   Drug: Sabizabulin;   Drug: Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator Sponsor:   Veru Inc. Not yet recruiting
Source: - Category: Research Source Type: clinical trials
In conclusion, PC‑B‑142CA can serve as a novel HER2‑positive breast cancer cell line for drug resistance studies; while PC‑B‑148CA is a novel TN breast cancer cell line suitable for metastatic and stemness‑related properties.PMID:34651665 | DOI:10.3892/or.2021.8205
Source: Oncology Reports - Category: Cancer & Oncology Authors: Source Type: research
J Cell Mol Med. 2021 Oct 15. doi: 10.1111/jcmm.16946. Online ahead of print.ABSTRACTBreast cancer, a hormone-dependent tumour, generally includes four molecular subtypes (luminal A, luminal B, HER2 enriched and triple-negative) based on oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2. Multiple hormones in the body regulate the development of breast cancer. Endocrine therapy is one of the primary treatments for hormone-receptor-positive breast cancer, but endocrine resistance is the primary clinical cause of treatment failure. Prolactin (PRL) is a protein hormone secreted by the pituit...
Source: J Cell Mol Med - Category: Molecular Biology Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Conferences | HER2 | Herceptin